secwatch.observer — SEC 8-K summary
======================================

Issuer:     DSS, INC. (DSS)
CIK:        0000771999
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001493152-24-003268
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DSS amends $12.86M promissory note with Impact BioMedical, extends maturity to 2030
--------------------------------------------------------------------------------

- Principal balance funded to $12,859,328.60, including $1,231,483.14 interest funding advanced Jan 17, 2024.
- Maturity extended to September 30, 2030; interest-only payments through Jan 2026, then monthly $126,380.80.
- Interest rate set at WSJ Prime + 0.50% (initial 9.00%); secured by blanket first lien on all Impact assets including patents.
- DSS is the lender and majority shareholder of Impact BioMedical, indicating continued related-party support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/0001493152-24-003268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-003268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer